TY - JOUR T1 - Genetic risk factors and Covid-19 severity in Brazil: results from BRACOVID Study JF - medRxiv DO - 10.1101/2021.10.06.21264631 SP - 2021.10.06.21264631 AU - Alexandre C. Pereira AU - Taniela Marli Bes AU - Mariliza Velho AU - Emanuelle Marques AU - Cintia E Jannes AU - Karina Ramos Valino AU - Carla L Dinardo AU - Silvia Figueiredo Costa AU - Alberto José da Silva Duarte AU - Alexandre Ricardo dos Santos AU - Miguel Mitne-Neto AU - Jose Medina-Pestana AU - Jose E Krieger Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/10/07/2021.10.06.21264631.abstract N2 - The Covid-19 pandemic has changed the paradigms for disease surveillance and rapid deployment of scientific-based evidence for understanding disease biology, susceptibility, and treatment. We have organized a large-scale genome-wide association study in Sars-Cov-2 infected individuals in Sao Paulo, Brazil, one of the most affected areas of the pandemic in the country, itself one of the most affected in the world. Here we present the results of the initial analysis in the first 5,233 participants of the BRACOVID study.We have conducted a GWAS for Covid-19 hospitalization enrolling 3533 cases (hospitalized Covid-19 participants) and 1700 controls (non-hospitalized Covid-19 participants). Models were adjusted by age, sex and the 4 first principal components. A meta-analysis was also conducted merging BRACOVID hospitalization data with the Human Genetic Initiative (HGI) Consortia results.BRACOVID results validated most loci previously identified in the HGI meta-analysis. In addition, no significant heterogeneity according to ancestral group within the Brazilian population was observed for the two most important Covid-19 severity associated loci: 3p21.31 and Chr21 near IFNAR2. Using only data provided by BRACOVID a new genome-wide significant locus was identified on Chr1 near the genes DSTYK and RBBP5. The associated haplotype has also been previously associated with a number of blood cell related traits and might play a role in modulating the immune response in Covid-19 cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe BRACOVID project received an unrestricted financial support from JBS S.A. Company, Sao Paulo, Brazil and from the general public under the HC-COMVIDA crowdfunding scheme (https://viralcure.org/c/hc). The funds were managed by Fundacao Zerbini and Fundacao Faculdade de Medicina, respectively.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the National Research Ethics Committee (CONEP) and Ethics Committee for the Analysis of Research Projects at HC FMUSP (CAPPesq), under the number 5025/20/054.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data regarding this study are available with the manuscript file. ER -